


## Natriuresis guided therapy in acute heart failure


### Conclusion

 A pragmatic natriuresis guided diuretic approach in patients with acute heart failure (AHF) significantly increases 24-hour natriuresis without impacting all-cause mortality or HF rehospitalisation.

### Impact on clinical practice

 Clinicians should consider natriuresis guided diuretic therapy as a first step to a personalised treatment approach in patients with AHF to improve decongestion.

### Study objectives

 The PUSH-AHF trial investigated the effectiveness of natriuresis guided diuretic therapy on natriuresis and clinical outcomes in patients with AHF.

### Study population

#### Patients

- AHF requiring treatment with intravenous (IV) loop diuretics

The inclusion and exclusion criteria were intentionally broad to enrol a contemporary, representative, all-comer AHF population.


#### Where?




University Medical Centre Groningen, the Netherlands

### Primary endpoints: $p < 0.025$ for each was considered statistically significant

#### 24-hour natriuresis



#### Combined endpoint of time to all-cause mortality or HF rehospitalisation at 180 days



### Who and what?

